This update includes a $5.7 million Series A financing announced by Dharmacon Research. Since GenomeWeb reported on the placement after the original deadline passed, the financing was not mentioned in the final tally. The update also removes from the list Applied Genomic Technology's $150 million placement. The article incorrectly listed the VC fund Applied Genomic Technology Capital as a genomics company. GenomeWeb regrets the error.
NEW YORK, Aug. 26 - A review by GenomeWeb found that pure-play genomic tool and technology companies reported raising about $102.7 million in private-equity cash since January, down slightly from the $115 million similar companies reported pocketing during the same eight-month period last year.
For the remainder of 2001, genomic firms reported raising more than $415 million, the brunt of which--some $300 million--appearing between September and Christmas.
According to VentureWire, a VC tracking firm, venture-capital interest in biotech companies, which includes genomic customers and a small number of vendors, actually increased 44 percent during the three months ended June.
But the tool and tech sector still has some catching up to do. Following is a glimpse of the eight VC investments reported since January 2002 and the 24 rounds reported throughout 2001.
[Editor's note: This list comprises only those private-equity rounds announced by genomic, proteomic, bioinformatic, and microarray companies, and reported by GenomeWeb. This list does not include government grants, equity investments tied to R&D collaborations, private stock placements, or any other form of cash infusion not related to venture capital.]
Dharmacon Research, Aug.27--$5.7 million
Zyomix, Series E, July 30--$27 million
HandyLab, Series B, July 25--$5.5 million
Hybrigenics, Series C, April 12--$14.8 million
Gyros, Series B, April 11--$36 million
Gentris, undisclosed round, March 19--$1.5 million
Beyond Genomics, undisclosed round, Feb. 13--$11 million
High Throughput Genomics, Series A, Jan. 21--$1.3 million
Syrrx, undisclosed round, Dec.26--$18.5 million
MitoKor, undisclosed round, Dec.20--$25 million
Avalon, Series B, Dec.17--$70 million
ExonHit, Series C, Dec.3--$26.8 million
Fluidigm, Series C, Nov.12--$34 million
Glycominds, undisclosed round, Nov.7--$7.1 million
Atto Bioscience, Series A, Oct.29--$3 million
GeneFormatics, Series C, Oct.17--$22 million
Protedyne, Series B, Oct.12--$12 million
Galileo Genomics, undisclosed round, Oct.10--$16.5 million
Sagres Discovery, undisclosed round, Oct.3--$20 million
Solexa, Series B, Sept.24--$12 million
EuroProteome, undisclosed round, Sept.17--$8.7 million
Entelos, undisclosed round, Sept.6--$25 million
LaunchCyte, undisclosed round, Aug.8--$700,000
Viaken, Series B, June 25--$13 million
DNAPrint, undisclosed round, June 18--$2 million
AlgoNomics, Series B, June 5--$1.5 million
DeveloGen, undisclosed round, April 18--$35 million
LifeSpan Biosciences, Series C, April 17--$19 million
Nanostream, Series B, March 30--$10 million
LumiCyte, undisclosed round, March 26--$20 million
Proteologics, undisclosed round, March 5--$14 million